

MARCH 16-17 2021

**IMMUNOLOGY
& INFLAMMATORY
DISORDERS**

COMPANY BOOK

100% DIGITAL EXPERIENCE

WWW.HYBRIDAYS.COM

Table of contents

Abbvie	03
Amgen	08
AstraZeneca	15
Bristol MyersSquibb	21
GSK	31
Institut Roche	37
Johnson & Johnson	43
MSD	48
Novartis	50
Pfizer	59
Roche Diagnostics	67
Sanofi	74
Servier	87
Takeda	94



Number of Countries 75

Headquarters Chicago, US

Company Size 47000

R&D Staff 9000

Annual Sales 2020 33,2 Billion US dollars

R&D Investment 5 Billion US dollars

>> Company description

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Our Principles : AbbVie's identity is shaped by the work we do - producing innovative medicines, continually investing in our pipeline, and giving back to create healthier, more vibrant communities.

Our approach: Collaborations are critical to our own success and the success of the industry. We are creating partnerships that make a difference

At AbbVie, we partner to achieve two important outcomes: deliver innovative medicines and make a remarkable impact on people's lives.

We start with a highly integrated approach to developing and sustaining our partnerships. We work as one connected unit with a commitment to establishing collaborations across the development continuum that will ultimately benefit patients and fuel scientific progress.

With a shared vision as our foundation, we align our capabilities to conduct groundbreaking science and bring innovative medicines to societies around the globe. From start to finish, we manage our partnerships for successful outcomes. Our partners and our strong team help make this possible.

Please visit us at www.abbvie.com

>> Therapeutic areas of interest including R&D listed by priority

Immunology: as a leader in immunology, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology. Our programs focus on investigating both targeted oral therapies and biologics. Our areas of interest include: Crohn's disease, ulcerative colitis, Psoriasis, atopic dermatitis, Rheumatology (RA, PsA, SpA), nNovel therapies for SLE, systemic sclerosis, Sjogrens syndrome, Fibrotic conditions associated with certain inflammatory conditions

Oncology: Solid tumors and hematologic malignancies, targeted therapies for regulated cell death, B-cell signaling, T-cell-engaging- and receptor-based approaches, immuno-oncology, next generations of targeted small molecules and targeted biologics

Neuroscience: Multiple sclerosis, Alzheimer's, Parkinson's and other neurodegenerative diseases that share proteinopathy mechanism with AD and PD

>> History of collaboration with academic teams or startups

Whether partnering with a business, academia or consortia, our goal is to create long-term mutually beneficial relationships. In 2020 and 2019, we announced collaborations and partnerships with :

- INSERM and OMS, to contribute to research efforts against COVID19
- Harvard University, to form the a Research Alliance to Address Emergent Viral Diseases,
- Utrecht University, Harbour BioMed and Erasmus Medical Center, Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19,
- Frontier Medicines, to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets,
- I-Mab and Genmab in oncology and immuno-oncology,
- Scripps Research (non profit organisation), in oncology, immunology, neurology and fibrosis
- Jacobio, to Advance SHP2 Inhibitors

>> Keywords

Immunology |Inflammatory |Partnership |Impact |Pipeline

Andrew Marc Anisfeld

Title/Position:

Vice President, Asset Leadership, Immunology

Background/CV

Current Position: Vice President, Asset Leadership, Immunology

Previous positions at AbbVie:

Global Medical Affairs Therapeutic Area Lead, Rheumatology and Global Medical Affairs Therapeutic Area Lead, Immunology Pipeline Strategy

Key previous positions:

- **Pfizer:** Global Program Medicine Development Lead Rheumatology, Senior Director, Global Medical Affairs Team Lead, Rheumatology and Global Medical Affairs Director, Rheumatology

- **Genentech/Roche:** Senior Medical Science Director, Rheumatology US Medical Affairs

Education:

- PhD, Departments of Biological Chemistry and Cardiology, University of California, Los Angeles (UCLA) David Geffen School of Medicine

- B.S., Cum Laude Biological Chemistry and Cell Biology. University of California, San Diego (UCSD)

Contact/Address

LinkedIn Url:

Contact: : andrew.anisfeld@abbvie.com

Heath M Guay

Title/Position:

Senior Scientific Director, Precision Medicine Immunology



Background/CV

Education:

Ph.D., Immunology

University of Pennsylvania School of Medicine, Philadelphia, PA

B.S., Biology, Magna Cum Laude

Siena College, Loudonville, NY

Industry Experience:

Sr. Scientific Director, Head of GI and Dermatology Precision Medicine

Immunology Clinical Development, Abbvie

Scientific Director

Translational and Biomarker Research, Takeda Pharmaceuticals

Co-Founder & Head of Research

Estrela Lupus Venture, Janssen R&D

Sr. Research Scientist

Research Immunology, Janssen R&D

Sr. Research Scientist, Head of Preclinical Lupus & B cell Biology Group

Wyeth Research, Inflammation Discovery Research, Immunopharmacology Group

Additional Research Experience:

UMASS Medical School, Laboratory of Raymond Welsh, Ph.D.

The University of Pennsylvania, Laboratory of Andrew J. Caton, Ph.D.

The University of Pennsylvania, Laboratory of Luis Montaner, DVM, Ph.D.

The NY State Department of Health, Laboratory of Arlene Ramsingh, Ph.D.

Contact/Address

LinkedIn Url:

Contact: heath.guay@abbvie.com

Ian McCaffery

Title/Position:

Vice President of Precision Medicine

Background/CV

Ian McCaffery is Vice President of Precision Medicine within development team. He is driving AbbVie vision of leveraging Companion Diagnostics and enhancing our Translational and Biomarker strategies across R&D. Ian McCaffery joined Abbvie in 2020

Before joining AbbVie, Ian has held leadership positions at several peer companies including Amgen as well as Genentech, where he was the Head of Companion Diagnostic Development. Most recently, Ian was Vice President and Head of Oncology Translational Research and Diagnostics at Janssen Pharmaceuticals where he built and led an integrated Biomarker and Companion Diagnostic organization in the U.S., Europe and China. At Janssen, Ian's team generated and leveraged clinical biomarker data as well as next-generation diagnostic tools to accelerate the development of novel targeted agents including the co-approval of erdafitinib and companion diagnostic assays in bladder cancer.

Education: Ian received his Ph.D. in Biochemistry and Molecular Biology from the University of Leeds in the United Kingdom.

Contact/Address

LinkedIn Url:

Contact: ian.mccaffery@abbvie.com

Joachim Vogt



Title/Position:

Director Search & Evaluation Western Europe

Background/CV

Joachim Vogt is Director Search & Evaluation Western Europe at AbbVie. He is responsible for the identification of European business opportunities across all indications and technologies of interest for AbbVie and serves as key contact for European partners, including academic institutions, biotech companies, venture capital, governments and non-profit organizations.

Joachim spent more than 15 years in the pharmaceutical and biotech industry in BD and research roles. He gained broad experience in the areas of in- and outlicensing of preclinical and clinical projects as well as research technologies. Before joining AbbVie, Joachim was Director of Early Stage Partnering at Roche, served as Senior Manager at Willex AG and was Head of IP Licensing at the tech transfer office Bayerische Patentallianz. Joachim holds a diploma in chemistry and received his PhD in protein crystallography at the University of Freiburg.

Contact/Address

LinkedIn Url:

Contact: joachim.vogt@abbvie.com



Number of Countries 100
Headquarters Thousand Oaks, California
Company Size 22 000
R&D Staff
Annual Sales 2020 \$23.4 billion
R&D Investment \$4.0 billion

>> Company description

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For further information:

https://wwwext.amgen.com/-/media/Themes/CorporateAffairs/amgen-com/amgen-com/downloads/fact-sheets/fact_sheet_amgen.pdf

>> Therapeutic areas of interest including R&D listed by priority

Inflammation
Cardiovascular diseases
Oncology
Bone health
Neurosciences
Nephrology

>> History of collaboration with academic teams or startups

>> Keywords

Lupus | Inflammatory bowel diseases | Chronic urticaria | T regulatory cells | Digital health

Hernan Picard

Title/Position:

Executive Medical Director Global Development, Thousand Oaks, CA; Inflammation Department

Background/CV

Contact/Address

LinkedIn Url:

Contact: hpicard@amgen.com

Nathalie Varoqueaux

Title/Position:

Executive Medical Director, Amgen France, Boulogne Billancourt

Background/CV

Contact/Address

LinkedIn Url:

Contact: nvaroque@amgen.com

Nestor Molfino

Title/Position:

Executive Medical Director Global Development, Thousand Oaks, CA; Inflammation Department

Background/CV

Contact/Address

LinkedIn Url:

Contact: nmolfino@amgen.com

Prista Charuworn

Title/Position:

Clinical Research Medical Director, Thousand Oaks, CA; Inflammation Department

Background/CV

Contact/Address

LinkedIn Url:

Contact: pcharuwo@amgen.com

Thibault de Chalus

Title/Position:

Innovation & Investment Program Lead, Amgen France, Boulogne Billancourt

Background/CV

Contact/Address

LinkedIn Url:

Contact: tdechalu@amgen.com

Véronique Chauvet

Title/Position:

Senior Medical Advisor, New Product General Medicine, Amgen France, Boulogne Billancourt



Background/CV

Contact/Address

LinkedIn Url:

Contact: vchauvet@amgen.com

>> Company description

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

>> Therapeutic areas of interest including R&D listed by priority

Focus on three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism and Respiratory & Immunology. Selectively active in the areas of infection, neuroscience and gastroenterology where we follow an opportunity-driven approach and often work through partnerships.

In respiratory, we aim to transform the treatment of asthma and COPD by driving earlier, biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.

With common pathways and underlying disease drivers across respiratory and immunology, we are following the science from chronic lung diseases to immune-driven disease areas, by focusing on five mid-to late-stage franchises with multi-disease potential in rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology and systemic eosinophilic-driven diseases.

>> History of collaboration with academic teams or startups

Numerous alliances, acquisitions and collaborations with peer companies, biotechs and academia enable us to enhance our portfolio and pipeline in our main therapy areas.

>> Keywords

SLE | Eosinophils | Gastroenterology | |

Alessandro SORRENTINO

Title/Position:

Immunology Medical Head - Global

Background/CV

Contact/Address

LinkedIn Url:

Contact: alessandro.sorrentino@astrazeneca.com

Caroline LAMBERT

Title/Position:

Senior Medical Advisor Respiratory&Immunology

Background/CV

AstraZeneca

Senior Medical Advisor Respiratoire & Immunologie

Lead AZ first Bx (Fasenra) launch in Severe Asthma Lead Fasenra Life Cycle Management in France

EU/CAN Medical Lead for Bx Tezepelumab in Severe Asthma

EU/CAN Lead for Bx Anifrolumab in Systemic Eryth Lupus

Background

09/2001

Université Lyon 1 Claude Bernard | *Lyon*

PhD Medical Doctorate: Médecine

09/2002

EM-Lyon | *Lyon*

Master Stratégie & Marketing

B2B Industrie: Marketing B2B

Contact/Address

LinkedIn Url:

Contact: caroline.lambert@astrazeneca.com

Charlotte LUPTON

Title/Position:

Global Medical Affairs Leader - Anifrolumab and Brazikumab

Background/CV

Contact/Address

LinkedIn Url:

Contact: charlotte.lupton1@astrazeneca.com

Gabriel THABUT

Title/Position:

Medical Director, Respiratory&Immunology

Background/CV

Contact/Address

LinkedIn Url:

Contact: gabriel.thabut@astrazeneca.com

Myriam GAMBERONI

Title/Position:

Associate Director External Alliances & Partnerships

Background/CV

AstraZeneca

- Develop and implement an academic partnership strategy
- Identify and elaborate strategic scientific collaborations

Business Developer Manager and Alliance Manager, Inserm Transfert, Paris

2013 – 2019

Business Development and Licensing in Oncology, Immuno-oncology and Immuno-inflammation therapeutic areas: Elaborate and negotiate scientific collaborations and licenses between academics and industrials

Alliance Manager: Management of 3 strategic alliances between academics and industrials (from 400k€ to 5 million euros per year)

Background

2013: ESSEC Business School (Paris – Singapore); Executive Master Strategy and Management of Health Industry

2009 - 2011: Post-doctoral fellow in Oncology and Scientific coordinator at Cellular and Cancer Signaling Unit, INSERM U938, St Antoine Hospital, Paris

2005 - 2008: Ph. D. of Molecular Biology (Virology, Regulation of IFN Signaling pathway), Pasteur Institute Paris and Lady Davis Institute Montreal. *Denis Diderot University of Paris VII*

Contact/Address

LinkedIn Url:

Contact: myriam.gamberoni@astrazeneca.com

>> Company description

Bristol Myers Squibb associe le meilleur de la biotechnologie et de l'industrie pharmaceutique pour développer des médicaments innovants destinés aux patients atteints de cancer ou d'autres maladies graves.
Notre vision unique : Transformer la vie des patients par la science.

>> Therapeutic areas of interest including R&D listed by priority

Hématologie, Oncologie, Immunologie, Cardiologie et Fibrose

>> History of collaboration with academic teams or startups

Recherche Clinique France (2019) : 45 molécules en développement, 1062 centres investigateurs, 6377 patients inclus dans les études en cours (dont 908 en 2019), 160 études cliniques en cours, 142 Investigators Sponsored Research, 14 études non interventionnelles.

Fondation BMS pour la Recherche en Immuno-Oncologie créée en 2015

#ExploreForCancer

>> Keywords

ONCOLOGIE | IMMUNOLOGIE | HEMATOLOGIE | CARDIOLOGIE | FIBROSE

David HARDEN

Title/Position:

Director of Business Development Search and Evaluation Lead for Cardiovascular, Fibrosis and Immunology

Background/CV



David Harden, M.S., M.B.A.

Director of Business Development Search and Evaluation Lead for Cardiovascular, Fibrosis and Immunology

Dave is currently the Search and Evaluation lead for Cardiovascular, Fibrosis, and Immunology therapeutic areas for the Bristol-Myers Squibb (BMS) business development group. In this role, he is responsible for proactive search and review of requests for potential partnerships as well as leading formal diligence processes for advanced opportunities. In 2020, Dave was a key contributor to the diligence process supporting the MyoKardia acquisition. Prior to joining business development, Dave served as the Head of Lead Discovery in the BMS discovery organization, leading teams responsible for discovery of chemical starting points that have resulted in 14 clinical candidates including the phase 3 molecule, deucravacitinib. Dave holds an advanced degree in Neuroscience from the University of Pittsburgh along with a Master's in Business Administration from Quinnipiac University.

Contact/Address

LinkedIn Url:

Contact: david.harden@bms.com

Jehan-Michel BEHIER

Title/Position:



Background/CV

Contact/Address

LinkedIn Url:

Contact: jehan-michel.behier@bms.com

Laurence D'AGAY

Title/Position:

Background/CV

Contact/Address

LinkedIn Url:

Contact: Laurence.DAgay@bms.com

Liliane LAMEZEC

Title/Position:

Directrice Médicale Innovative Medicines



Background/CV

Contact/Address

LinkedIn Url:

Contact: liliane.lamezec@bms.com

Luigi RAVAGNAN

Title/Position:

Background/CV

Contact/Address

LinkedIn Url:

Contact: luigi.ravagnan@bms.com

Nadine KARAM

Title/Position:



Background/CV

Contact/Address

LinkedIn Url:

Contact: nadine.karam@bms.com

Radu VADANICI

Title/Position:

Background/CV

Contact/Address

LinkedIn Url:

Contact: radu.vadanici@bms.com

Valérie VAIARELLI

Title/Position:

Background/CV

Contact/Address

LinkedIn Url:

Contact: valerie.vaiarelli@bms.com

Virginie VANNIER-MOREAU

Title/Position:

Background/CV

Contact/Address

LinkedIn Url:

Contact: Virginie.Vannier-Moreau@bms.com



Number of Countries 95

Headquarters London UK

Company Size 99000

R&D Staff 11000

Annual Sales 2020 33,7 bn £

R&D Investment 4,6 bn £

>> **Company description**

GSK is a science led global healthcare company. We have 3 businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products which are used by millions of people around the world, helping them to do more, feel better and live longer.

>> **Therapeutic areas of interest including R&D listed by priority**

Our main therapeutic area of interest are respiratory, oncology, immunoinflammation, human genetics, vaccines, infectious diseases including bacterial, viral and parasitic infections. We also have interests in neglected tropical diseases and in WHO's priority diseases which are HIV/AIDS, tuberculosis and malaria.

>> **History of collaboration with academic teams or startups**

GSK has a strong history of collaborations with both academic teams and start-ups. During the past decade through the DPAC (Discovery Partnership with Academia) initiatives GSK set numerous collaborations with academic groups. These collaborations included research projects at all stages of maturations from very early stages of target validation up to clinical phase 1 and 2. In addition these collaborations were done in multiple therapeutic areas and were driven by science quality and innovation.

>> **Keywords**

||||

Anne-Charlotte de GOUVILLE

Title/Position:

Medical manager portfolio assets



Background/CV

Anne-Charlotte is PharmD, PhD.

After her PhD she started working in preclinical research in the cardiovascular and metabolic area at the french GSK research center. She subsequently moved to clinical research and was involved in programmes in type 2 diabetes, dermatology, cardiology.

Since 2016 she works in medical affairs at GSK french LOC where she is in charge of the portfolio of future speciality medicines.

Contact/Address

LinkedIn Url:

Contact: anne-charlotte.m.degouville@gsk.com

jeremy GRIGGS

Title/Position:

GSK Worldwide Business Development - Immunology

Background/CV

Jeremy is a Senior Director in GSK's Immunology Business Development Team. He is a biologist by training and Fellow of the Royal Society of Biology. Jeremy has extensive knowledge of the drug discovery process, drawn from over fifteen years of post-doctoral experience in the pharmaceutical industry with a broad-ranging professional network within Industry and Academia.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/griggsjeremy/>

Contact: jeremy.griggs@gsk.com

Marc-André WURBEL

Title/Position:

PhD and Scientific Director



Background/CV

Background: Marc-André Wurbel, PhD is a group leader in Genomic Immunology within GSK Adaptive Immunology Research Unit. Based in Cambridge, his group is part of human genetics and functional genomics leveraging strategy to identify and validate immune targets in order to deliver differentiated medicines to autoimmune indications with unmet need. A critical component to this approach is the partnerships that the team has with Human Genetics, Functional Genomics, and external collaborators focused on CRISPR-based genetic screening, variant-to-gene and variant-to-function mapping, and immunophenotyping.

Marc-André received his PhD in Immunology from “Université de la Méditerranée, Aix-Marseille II” under Dr. Bernard Malissen’s supervision at the “Centre d’Immunologie Marseille-Luminy” and performed his post-doctoral fellowship at Harvard Medical School-affiliated Boston Children’s Hospital where he led later on IBD-related research as a junior faculty within the Division of Gastroenterology. Prior to joining GSK in 2019, Marc led a biology group at AbbVie within the department of Pharmacology working on early target validation in autoimmunity, mucosal immunology and epithelial barrier functions.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/marc-wurbel-08b87a4/>

Contact: marc.a.wurbel@gsk.com

Mercedes LOBERA

Title/Position:

Senior Director, Genomic Immunology, Adaptive Immunity Research Unit



Background/CV

Mercedes Lobera, Ph.D., leads the Genomic Immunology group within the Adaptive Immunity Research Unit at GSK. Based in Cambridge, MA and Stevenage (UK), the team is focused on leveraging human genetics and functional genomics to identify and validate immune targets in order to deliver differentiated medicines. A critical component to this strategy are the partnerships that the team has with Human Genetics, Functional Genomics, and external collaborators focused on CRISPR-based genetic screening, variant-to-gene and variant-to-function mapping, and immunophenotyping.

Mercedes has been at GSK since 2009, originally as part of Tempero Pharmaceuticals (a biotech created and fully funded by GSK), where she held roles of increasing seniority in chemistry and drug discovery, with a focus on pathways modulating Th17 and regulatory T cell function. Prior to joining GSK, Mercedes started her career at Predix Pharmaceuticals working on CNS and inflammation targets. Mercedes received her PhD and M.Sc. in Organic Chemistry from Brandeis University, and her B.Sc. in Chemistry from the University of Barcelona.

Contact/Address

LinkedIn Url: (14) Mercedes Lobera | LinkedIn

Contact: Mercedes.x.lobera@gsk.com

Rab PRINJHA



Title/Position:

Head of Adaptive Immunity Research

Background/CV

Rab Prinjha leads the Adaptive Immunity and Immuno-Epigenetics Research Unit and cofounded the GSK Biology Council and is an elected fellow of the Academy of Medical Sciences and the Royal Society of Biology. He represented GSK on the EU-EFPIA Board.

He currently is on the OpenTargets Governance Board, the UK MRC PSMB Board and is on the SAB of the MRC UK Human Genetics Unit and on the Board of the Academy of Medical Sciences. He is a co-founder and board member of the Milner Therapeutics Consortium. His group has already advanced multiple medicines into clinical studies with many more in the pipeline and has collaborated with many world leading labs leading to an extensive high impact publication record. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy's Hospital and PhD in molecular cellular immunology at UCL after a degree in Biotechnology at King's College London.

Contact/Address

LinkedIn Url: https://www.linkedin.com/in/rabprinjha/?lipi=urn%3Ali%3Apage%3Ad_flagship3_feed%3B7ACFZdc2QU%3D%3D

Contact: Rabinder.Prinjha@gsk.com



Number of Countries Over 100
Headquarters Basel (Switzerland)
Company Size 97,735 people
R&D Staff
Annual Sales 2020 61,466 Million Swiss Francs
R&D Investment 11,696 Million Swiss Francs

>> Company description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, and its focus is on creating truly innovative medicines and diagnostic tests in areas of unmet medical need. Roche is also a leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2019, the Roche Group employed 97,735 people worldwide, invested 11,696 million Swiss francs in R&D and posted sales of 61,466 million Swiss francs. For more information, please visit roche.com. All trademarks used or mentioned in this release are protected by law.

>> Therapeutic areas of interest including R&D listed by priority

The research areas are cancerology, neuroscience, immunology, infectious diseases, rare diseases and ophthalmology.

>> History of collaboration with academic teams or startups

Since 2009, it has managed over 180 scientific programs to be carried out and represents an investment of over 45 million euros in "public-private" partnerships which have given rise to 72 publications and 6 patents. Our main partners are Centre Léon Bérard, CNRS, Institut de Myologie, Fondation Fondamentale, Institut Curie, Institut Pasteur, Institut Bergonié, Gustave Roussy, Inserm, Unicancer, etc ...

>> Keywords

Reverse Translational Research | Comprehensive longitudinal patient data. | Human Artificial Intelligence Machine Learning Partnership | Microbiome | Novel Ex-vivo systems, Novel biotechnology; generation of New meaningful data

Camille Brochier, Ph.D



Title/Position:

Scientist Project Manager

Background/CV

Training and academic background

2018 : Master in Management - 2018 | ESCP Europe, France/UK - Specialized in Biopharmaceutical Management

2013-2017 : Junior Faculty (Instructor in Neuroscience) - Weill Cornell Medicine, New York, NY. Designed and directed an independent research project leading to the discovery of a new biomarker for nerve regeneration in the central nervous system (published in PNAS as corresponding author)

2007-2013 : Postdoctoral Fellow - Burke Neurological Institute, Weill Cornell Medicine, New York, NY. Designed and performed research in the field of neurodegeneration and neurorepair

2007 : Ph.D. in Molecular Biology and Genomics - Atomic Energy Commission & Université Paris France

Industry background

2016- Present: Scientific Partnerships Project Manager Institut Roche, France - dedicated to Roche-Genentech external collaboration

Scouting, implementation and scientific follow up of collaborative preclinical and translational projects with academic research lab in collaboration with Roche R&D in Oncology, Hematology and Immunology

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/camille-brochier/>

Contact: camille.brochier@roche.com

Hamasseh SHIRVANI, Ph.D



Title/Position:

Scientist Project Manager

Background/CV

Training and academic background

2015-2016: University diploma GBM (Biological and Medical Engineering) Innovation strategy in the biomedical companies and promotion of scientific research/ Analysis of needs of the biomedical sector, market research and management risk, UPMC

2012-2016: Post Doctoral Fellowship in Biology & Chemistry of radiations, cell signaling and cancer Dep, Curie Institute, France, Project leader "Leading of a scientific innovative project to study and develop new therapeutic strategies in the case of a pediatric brain tumor in mouse models

2007-2012: PhD in Biomedical Sciences; Pharmacologie, Biologie cellulaire et moléculaire, University of René Descartes, Paris 5

2005-2007: Master of Neurosciences and Cellular Signalization, Paris IX University

2000-2003: Bachelor's degree sciences, Beheshti University, IRAN, Teheran

Industry background

2016- Present: Scientific Partnerships Project Manager Institut Roche, France - dedicated to Roche-Genentech external collaboration, Scouting, implementation and scientific follow up of collaborative preclinical and translational projects with Roche R&D in Oncology and Immunology, Infectious Diseases Areas

Contact/Address

LinkedIn Url:

Contact: hamasseh.shirvani@roche.com

Magnus Fontes, Ph.D

Title/Position:

General Manager



Background/CV

Training and academic background

1991 : Graduate degree from Lund University

1997 : Degree of Doctor of Philosophy in Engineering in Mathematics from Lund University

2002 : Habilitation in Mathematics from Lund University in 2002

2011 : Awarded the distinction of ETP (Excellent Teaching Practitioner) by the Pedagogical Academy at the Faculty of Engineering at Lund University

2000 : Awarded the student prize for best professor at the Faculty of Engineering at Lund University

2003-2014: Head of the Centre for Mathematical Sciences at Lund University, Lund, Sweden

2014-2017: Director of International Relations at the Centre for Bioinformatics Biostatistics and Integrative Biology (C3BI), Institut Pasteur, Paris, France

2014-2017: Head of the International Group for Data Analysis at Institut Pasteur, Paris, France.

Industry background

August 2020-present : General Manager Institut Roche, Paris, France

January 2018- August 2020 Principal Scientist and Head of Systems Immunology & Reverse Translation, Cancer Immunology, Genentech, South San Francisco, California, USA.

2018-2020 Professor of Clinical Bioinformatics and Genomic Medicine at Copenhagen University and Rigshospitalet, Copenhagen, Denmark

2014-2017: Director of International Relations at the Institut Pasteur Centre for Bioinformatics, Biostatistics and Integrative Biology (C3BI) and Head of the International Group for Data Analysis at Institut Pasteur, Paris

Contact/Address

LinkedIn Url:

Contact: Magnus.fontes@roche.com

Marion Psomiades, Ph.D

Title/Position:

Scientist Project Manager



Background/CV

Training and academic background

2019-2020: Specialized Master in Biotechnologies Management at EM Lyon Business School, France

2014-2018 PhD in Neurosciences, CRNL- Doctoral School NSCo 476 « Neurosciences et cognition », Claude Bernard Lyon 1 University, France.

2012-2014 : Master in Neurosciences, Claude Bernard Lyon 1 University, France.

Industry background

2020 - Present: **Scientific Partnerships Project Manager Institut Roche**, France - Scouting, implementation and scientific follow up of collaborative preclinical and translational projects with academic research lab in collaboration with Roche R&D in Neurosciences, Ophtalmology and Rare Diseases.

Contact/Address

LinkedIn Url:

Contact: marion.psomiades@roche.com

Myriam Ly - Le Moal, Ph.D



Title/Position:

Scientist Project Manager

Background/CV

Training and academic background :

2008- 2013: PhD in Neurosciences, UPMC (Paris VI), Neurosciences, MBA of Collège des Ingénieurs
Preclinical research subject: Therapeutic targets for Alzheimer's disease

2007-2008: Master1, Master2 Integrative Biology and Physiology specialism in Neurosciences, UPMC (Paris VI)

2007: Master1 Scientific Communication, Journalism Denis Diderot University (Paris VII)

2015 - 2016 : Senior Grant Manager - Institut Pasteur - Coordination and conception of national and international collaborative projects

Feb 2015- Aug 2015 : Research Engineer- Project Coordinator - ARS - Inserm.

Industry background

2016- Present: **Scientific Partnerships Project Manager Institut Roche**, France - Scouting, implementation and scientific follow up of collaborative preclinical and translational projects with academic research lab in collaboration with Roche R&D in Neurosciences, Ophtalmology and Rare Diseases.

Contact/Address

LinkedIn Url:

Contact: myriam.ly-le_moal@roche.com



Number of Countries 175
Headquarters New Brunswick, N.J, USA
Company Size 132000 employees
R&D Staff
Annual Sales 2020 \$82b
R&D Investment \$11.4b

>> Company description

Johnson & Johnson is the world's largest and most broadly based healthcare company. Since its founding in 1886, innovation has been in Johnson & Johnson's DNA.

Its innovation engine, Johnson & Johnson Innovation, focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies.

Under the Johnson & Johnson Innovation umbrella of businesses, you can connect with us through our:

- Innovation Centre to accelerate collaborations with early stage innovation
- JLABS, to incubate and provide lab facilities to startup companies
- JJDC, Inc. for strategic corporate VC equity investment and seed funding
- Janssen Business Development works with established biotech and pharma companies at later stages of development

We provides scientists, entrepreneurs, emerging and established companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. We create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients.

For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

>> Therapeutic areas of interest including R&D listed by priority

CARDIOVASCULAR & METABOLISM - Metabolism - Retinal Diseases - Thrombosis

IMMUNOLOGY - Gastroenterology - Rheumatology - Immuno Dermatology - IL-23 Pathway

INFECTIOUS DISEASES & VACCINES - Hepatitis - Respiratory Infections - Bacterial & Viral Vaccines

NEUROSCIENCE - Mood Disorders - Neurodegenerative Disorders - Glutamatergic Pathway Diseases

ONCOLOGY - Prostate Cancer - Solid Tumor Targeted Therapy - Immuno-Oncology - Hematologic Malignancies

PULMONARY HYPERTENSION - Pulmonary Arterial Hypertension

PLATFORMS - Small Molecule & Protein Therapeutics - RNA Therapeutics, Gene Therapy - Cellular & Viral Therapeutics

- Data & Analytics

>> History of collaboration with academic teams or startups

Please visit https://jnjinnovation.com/sites/jji/files/2020-06/JnJ_Spotlight_Innovation_June%202020_Final.pdf

Examples of collaborations: Huma in Health Technology, Lava Therapeutics in Oncology, Exonate in Retinal disease, UK Biobank (Data Science), Dementia Consortium (Neuroscience) etc.

>> Keywords

target discovery and validation |translational research |complement pathway |nucleic acid sensing |inflammasome

Jason Witherington

Title/Position:

VP Immunology Lead EMEA

Background/CV

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/jason-witherington-8b881ba/>

Contact: JWitheri@ITS.JNJ.com

Jennifer Bell

Title/Position:

Senior Director Immunology

Background/CV

Contact/Address


LinkedIn Url: <https://www.linkedin.com/in/jennifer-bell-393b7a19/>

Contact: JBell11@ITS.JNJ.com

Pierre Quelet

Title/Position:

Dir Business Development Janssen France



Background/CV

Contact/Address

LinkedIn Url:

Contact: pquelet@its.jnj.com

Siau BAI

Title/Position:

New Venture Lead



Background/CV

PhD in Molecular and Cellular Biology

Business Development in technology transfer offices (King's College, Institut Pasteur) and in Pharma (Ipsen)

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/siaubai/>

Contact: sbai3@its.jnj.com



Number of Countries more than 140 countries
Headquarters Kenilworth, New Jersey, USA
Company Size 71 000 employees
R&D Staff 15 600 employees
Annual Sales 2020
R&D Investment \$9.9B in 2019

>> Company description

MSD is a global leader in delivering innovative health solutions through its medicines and vaccines. MSD demonstrate its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD is known as Merck in the United States and Canada. MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives.

Today, MSD continue to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.

History :

Since 1891, MSD researchers have helped to find new ways to treat and prevent illness — from the discovery of vitamin B1, to the first measles vaccine, to cold remedies and antacids, to the first statins to treat high cholesterol. Today, as a research-intensive biopharmaceutical company, we're focused on making important scientific advancements within vaccines, infectious diseases, immuno-oncology.... While we are proud of our past, we are enthusiastic about the future. We aim to create a healthier, brighter future for people around the world.

Discovery & development :

We aspire to be the premier, research-intensive biopharmaceutical company. We bring creative minds together to transform world-class science into life-changing medicines and vaccines.

>> Therapeutic areas of interest including R&D listed by priority

MSD focus on innovation to deliver medicines and vaccines that may help millions of people. <https://www.merck.com/research-and-products/product-pipeline/>

In oncology : MSD researchers and scientists brings together a deep understanding of genomics, biology and the immune system to advance the way we fight cancer.

In Vaccins : We've been discovering, developing and delivering vaccines to help prevent disease around the world for over 100 years.

In Infectious diseases : 35 years committed to research in HIV. 40+ investigator-initiated antimicrobial stewardship programs funded across the globe.

Ebola : Is an exemple of partnership to combat a deadly virus.

COVID-19 : https://www.merck.com/wp-content/uploads/sites/5/2020/10/COVID-19-Research-Efforts_01_25_2021_5PM_01.pdf

Antibiotics : Continuing research and striving for improvements in the use of antibiotics.

Cardio-metabolic disorders

>> History of collaboration with academic teams or startups

We recognize that individuals or companies cannot successfully develop medicines single-handedly. Most cases of true innovation come from robust and honest collaboration among individuals and organizations with diverse backgrounds and capabilities, brought together by the idea of improving human health.

We collaborate with external researchers and other members of the biopharmaceutical industry through participation in selected scientific consortia. Consortia are an important mechanism by which researchers can work together in a precompetitive manner to address complex scientific challenges common to all parties.

As part of our R&D strategy, we pursue opportunities to establish external alliances with a broad range of partners that complement our internal research capabilities, including research collaborations and licensing agreements for preclinical and clinical therapeutic candidate

>> Keywords

||||

Michel de Baar

Title/Position:

Executive Director, BD&L Europe



Background/CV

Michel is a business development and licensing professional with experience in all steps of business development and transaction processes within the global pharmaceutical, biotechnology and diagnostics industries. He joined the Global Business Development & Licensing (BD&L) team of MSD after having had BD&L roles at various biotech companies and a research institute. The goal for the BD&L team is to augment the pipeline for MSD. Within the team, Michel is responsible for search and evaluation of opportunities in Europe and the Middle East in the therapeutic areas of Infectious Diseases & Vaccines, Cardiometabolic - Renal & Ophthalmology, and Respiratory & Immunology.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/mpdebaar>

Contact: michel.de.baar@msd.com

Number of Countries 155
 Headquarters Novartis International AG Basel
 Company Size 109 000
 R&D Staff 23 000 (including 5 600 from NIBR)
 Annual Sales 2020 47,4 bn\$
 R&D Investment 9,4 bn\$

>> Company description

We reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

>> Therapeutic areas of interest including R&D listed by priority

On the theme of Immunology and Inflammatory Disorders, we focus on:

NEUROSCIENCE:

Multiple Sclerosis
 Migraine
 Spinal Muscular Amyotrophy
 SLA
 Depression (melancholia)
 Schizophrenia
 Huntington disease
 Alzheimer's disease
 PSP (Steele Richardson)
 Parkinson disease

Additionally, we are committed to the research of peripheral neuropathic pain, a chronic and debilitating condition.

IMMUNOLOGY, HEPATOLOGY & DERMATOLOGY:

Moderate-to-severe auto inflammatory skin diseases, including psoriasis, chronic spontaneous & inducible urticaria, atopic dermatitis, acne and lichen planus
 Skeletal diseases including axial spondyloarthritis and psoriatic arthritis, osteoarthritis
 Rare Diseases as CAPS, Periodic fever syndromes, Sjogren Syndrome, Systemic Lupus and Renal Lupus, Giant cell arthritis and ultra rare dysfunction (NLRC4)
 Non-viral liver diseases including nonalcoholic steatohepatitis (NASH)

>> History of collaboration with academic teams or startups

Our research benefits from an external network of more than 300 academic and 100 industry alliances focused on areas of mutual scientific interest. Collaborations can boost efficiency and accelerate progress by facilitating access to ideas, capabilities and talent not always available within our walls. By joining forces with external innovators to pursue shared scientific interests, we can increase the breadth and depth of the science covered.

We are partnering closely with academics in RWE data generation projects (post marketing studies), fundamental research in relation with center for biomedical research NIBR. We are embracing partnerships with start-up notably in the area of digital medicine and companion apps for a better identification, follow up in clinical studies and in real life.

>> Keywords

Patient Access | Patient Outcomes | Patient Pathway | Pragmatic Designs | Real World Evidence

Chiara PERELLA

Title/Position:

Global Brand Medical Director Early Products Rheumatology

Background/CV

Contact/Address

LinkedIn Url:

Contact: chiara.perella@novartis.com

Christian LOESCHE

Title/Position:

Global Executive Director Dermatology at NIBR

Background/CV

Contact/Address

LinkedIn Url:

Contact: christian.loesche@novartis.com

Coraline BELLAGARDE

Title/Position:

Medical Group Leader Dermatology France

Background/CV

Contact/Address

LinkedIn Url:

Contact: coraline.bellagarde@novartis.com

Eric RAPONI

Title/Position:

Medical Group Leader Neuroscience France

Background/CV

Contact/Address

LinkedIn Url:

Contact: eric.raponi@novartis.com

Florian VON RAISON

Title/Position:

Global Clinical Development Head Neuroscience

Background/CV

Contact/Address

LinkedIn Url:

Contact: florian.von_raison@novartis.com

Karin RERAT

Title/Position:

Senior Medical Advisor Neuroscience France

Background/CV

Contact/Address

LinkedIn Url:

Contact: karin.rerat@novartis.com

Nicolas BRUNO

Title/Position:

Medical Head Immunology, Hepatology & Dermatology France

Background/CV

Contact/Address

LinkedIn Url:

Contact: nicolas.bruno@novartis.com

Patrick MESHAKA

Title/Position:

Executive Medical Director Pharma France

Background/CV

Contact/Address

LinkedIn Url:

Contact: patrick.meshaka@novartis.com



Number of Countries 125
Headquarters New York
Company Size 88300
R&D Staff
Annual Sales 2020 \$51,8 B
R&D Investment \$8,0 B

>> **Company description**

About Pfizer: Breakthroughs That Change Patients' Lives®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

>> **Therapeutic areas of interest including R&D listed by priority**

Please visit us at : <https://www.pfizer.com/science/therapeutic-areas>

>> **History of collaboration with academic teams or startups**

Please visit us at : <https://www.pfizer.com/partners>

>> **Keywords**

||||

Arpita Maiti, PhD



Title/Position:

Executive Director & Global Head, Emerging Science & Innovation Lead - Inflammation & Immunology Worldwide Research & Development & Medical Pfizer, Inc.

Background/CV

- Leads scouting of external opportunities (Idea to Candidate) and academic collaborations for Inflammation & Immunology (I&I) and the Centers for Therapeutic Innovation (CTI), at Pfizer.
- Leads strategy and partnering efforts in the microbiome and cellular senescence for Pfizer.
- Prior to Pfizer, led R&D alliance management at Vertex Pharmaceuticals and Cell Biology/Drug Screening at Angiotech Pharmaceuticals.
- Trained as an immunologist with a PhD and MSc in Immunology from University of British Columbia and a BSc from Trinity College, University of Toronto.
- Co-organized the 12th World Congress on Inflammation 2015, served on the board of the Inflammation Research Association in numerous positions, including as its President (2012-14); currently on the Executive Committee of the International Association of Inflammation Societies.

Contact/Address

LinkedIn Url:

Contact:

Cara M.M. Williams, PhD



Title/Position:

Vice President Preclinical Biology, Inflammation & Immunology Research Unit

Background/CV

Dr Williams earned her PhD (Immunopharmacology), from Liverpool University, England UK and completed her postdoctoral studies on mast cell biology, at Harvard University- Beth Israel Deaconess Medical Center. She then moved to Stanford University, Palo Alto CA. to continue her research into mast cell function in health and disease. Nevertheless, as a devoted drug discovery pharmacologist with an interest in turning basic research into new breakthroughs for patients, Cara moved into the preclinical drug discovery world of biotech/pharma. Now with ~ 20 years of R&D experience under her belt, she leads the Preclinical Biology research division within the Inflammation & Immunology Research Unit at Pfizer Inc. Her areas of drug discovery research focus center around developing new therapeutics for the treatment of autoimmune diseases, IBD and dermatological diseases.

Contact/Address

LinkedIn Url:

Contact:

Jean-Baptiste Telliez, Ph.D

Title/Position:

Senior Director, Head of In-vitro Pharmacology Inflammation & Immunology Research Unit Pfizer



Background/CV

Dr. Telliez received his BA in Biochemistry from the University of Lille I and his Ph.D. in Molecular Biology from University of Lille I studying the transcriptional regulation of the oncogene Ha-ras. Following his Ph.D., he joined the laboratory of Dr. Larry Feig at Tufts University studying the role of GRF in Ras signaling. He then joined Genetic Institute/Wyeth working in the TNF signaling field prior to leading kinase inhibitor programs most notably against MK2. He subsequently led a group of biologists working in cytokine signaling and JAK inhibition leading to four JAK inhibitor assets currently in phases 2&3 of clinical development for multiple inflammatory diseases. He currently leads the in vitro pharmacology group within I&I supporting programs from early development to deliver clinical ready assets.

Contact/Address

LinkedIn Url:

Contact:

Nathalie ter Wengel, M.D.

Title/Position:

European Lead Worldwide Business Development



Background/CV

Nathalie ter Wengel M.D. is the European Lead Worldwide Business Development at Pfizer, where she is responsible for establishing new collaborations and exploring global licensing and other corporate development opportunities across all therapeutic areas that Pfizer is interested in with European companies. Previous to this role, she was the European Head for External Science & Innovation at Pfizer. Nathalie obtained her Doctor of Medicine degree at the Vrije Universiteit in Amsterdam. She has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in Internal Medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father's illness that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, where she served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in the partnering of filgotinib.

Contact/Address

LinkedIn Url:

Contact:

Ulrich Zügel, PhD



Title/Position:

Senior Director, Emerging Science & Innovation Lead - Inflammation & Immunology Europe, Pfizer Worldwide R&D

Background/CV

Ulrich Zügel holds a PhD in Immunology and is the Emerging Science & Innovation Lead - Inflammation & Immunology (I&I) Europe at Pfizer. He is responsible for scouting of preclinical partnering opportunities in Europe and establishing new collaborations in the I&I space. Ulrich has more than 20 years of international experience in Pharma R&D. Prior to joining Pfizer, Ulrich held several senior management positions in R&D. From 2016 - 2018 he was Head of Preclinical Drug Discovery on siRNA therapeutics & Site Head Silence Therapeutics GmbH, Berlin, Germany. Before that he had different management positions in drug discovery at BAYER AG and Schering AG, Berlin, Germany. During his career he successfully delivered numerous candidates to development in different disease areas. His academic career included postdoctoral work at the La Jolla Institute for Allergy and Immunology in San Diego, USA and the University of Ulm, Germany. He is author of >50 scientific publications.

Contact/Address

LinkedIn Url:

Contact:

Valerie Clerin, Ph.D

Title/Position:

Senior Director, Pfizer I&I Research Unit, Cambridge MA, USA



Background/CV

Valerie is a Research Project Leader in the Inflammation and Immunology Research Unit at Pfizer in Cambridge MA. She is responsible for leading the development of novel therapeutics for Inflammatory Bowel Disease and Rheumatoid Arthritis. Valerie has over 18 years of experience at Pfizer and Wyeth, working as a scientific leader in early drug discovery research, preclinical drug development and clinical asset development across multiple disease areas, including autoimmune diseases, atherosclerosis and thrombosis, heart failure, diabetic kidney disease, mineral and bone disorders, neuroinflammation and hemophilia. Valerie holds a Master degree in Mechanical Engineering from Ecole Centrale de Nantes in France and received her Ph.D. in Cardiovascular Bioengineering from University Paris 12. She completed her post-doctoral fellowship in the Institute for Medicine and Engineering at the University of Pennsylvania where she worked on new approaches to vascular tissue engineering.

Contact/Address

LinkedIn Url:

Contact:

Wendy Peters, PhD



Title/Position:

Senior Director, Emerging Science & Innovation Lead - Inflammation & Immunology,
Pfizer Worldwide R&D

Background/CV

Wendy has worked in Immunology research in the Bay area for over 20 years, first in academia, then in biotechnology companies and now large Pharma.

Wendy received her PhD in Immunology from Manchester University in the UK studying T cell subsets and susceptibility to Rheumatoid Arthritis, and completed her postdoctoral work at the Gladstone Institutes, UCSF, in the area of Chemokines and infectious disease. She went on to join the Gladstone faculty and received NIH funding for her research on chemokines and Anthrax pathogenesis.

In 2007 Wendy moved to industry and led research projects at Medimmune Vaccines working on the prevention of HSV-2, and at Bayhill Therapeutics examining the use of DNA vaccines for the treatment of autoimmune disease. This was followed by a position at the oral vaccine company Vaxart Inc where she led preclinical research on Influenza, and HSV-2 vaccine programs.

In 2015 she moved into the business development world and joined Sanofi's External Science and Partnering Group where she was charged with the search and evaluation of external assets in the area of immunology and inflammation. Wendy is currently a Senior Director in the Emerging Science and Innovation group at Pfizer where she scouts for academic collaborations as well as partnerships in the preclinical biotech space.

Contact/Address

LinkedIn Url:

Contact:



Number of Countries world wide
Headquarters Basel
Company Size 97735
R&D Staff 19500
Annual Sales 2020 61,46 Mds
R&D Investment 11,7 Mds

>> Company description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

>> Therapeutic areas of interest including R&D listed by priority

Technology in medicine is progressing at a rapid pace. We lead the way with innovations in diagnostic solutions helping transform healthcare for patients. Diagnostics play a leading role in disease prevention/management and in meeting increasingly complex healthcare challenges. IVD influence two-thirds of clinical decision making, despite accounting for about 2% of total healthcare spending. Our commitment to R&D means we bring to the market advanced and integrated solutions in diagnostic testing, laboratory efficiency and decision support tools. We combine science, data and insights to transform Diagnostics. Our high-value assays, digital solutions and services deliver certainty, better decisions and outcomes to help people lives. We are further expanding our industry-leading reagent menu in the following disease areas: Infectious Disease, Oncology, Cardiology and in other disease areas

>> History of collaboration with academic teams or startups

Partnering with various stakeholders from the healthcare ecosystem plays a crucial role in bringing innovation to the market/to patients. Particularly for new digital solutions academia and startups are a huge driver of innovation. Beyond many already existing collaborations with academia and industry, Roche has also initiated the digital health accelerator Startup Creosphere in 2018. As part of the program, with locations in Munich, Silicon Valley and Singapore, Roche has been collaborating with more than 30 startups. Collaborations in areas such as advanced data analytics, clinical decision support and disease management include co-development, pilot projects with patients and healthcare providers, clinical studies as well as commercial agreements.

>> Keywords

innovation |diagnostic testing |advanced data analytics |clinical decision support |biomarker

Antoine Vimont

Title/Position:

Healthcare development



Background/CV

Antoine Vimont, 40 ans, a rejoint le Comité de Direction de Roche Diagnostics France en septembre 2018. En tant que directeur de la division HealthCare Development, il est notamment en charge du Business Development et de l'Accès au Marché, du Consulting Stratégique ainsi que des Affaires Médicales. Il est depuis septembre 2020 également Secrétaire Général du SIDIV.

Docteur en Sciences et Ingénieur Agronome de formation, il a auparavant occupé diverses fonctions de Direction au sein des Groupes Eurofins, Roullier ou encore bioMérieux.

Contact/Address

LinkedIn Url:

Contact: antoine.vimont@roche.com

Bernhard Risse

Title/Position:

Head R&D early development and reagent design



Background/CV

Head of Roche Centralized and Point of Care R&D Early Development & Reagent Design

Bernhard is leading a global R&D department comprising a deep domain knowledge related to new biomarker and system technology assessments, reagent design technologies and biostatistics & data science developments to support Diagnostics reagent and system pipeline and development programs as well as Pharma biomarker teams.

He started his professional career 27 years ago with Roche Diagnostics in Switzerland after completing a postdoctoral fellowship-training program. Bernhard obtained his PhD in Physical Biochemistry from the University of Regensburg.

Contact/Address

LinkedIn Url:

Contact: bernhard.risse@roche.com

Christian Zaugg

Title/Position:

Head MSA clinical science CPS



Background/CV

Christian Zaugg is the Global Head of Clinical Science in Centralised and Point of Care Solutions (CPS) at Roche Diagnostics, leading a team of medical experts responsible for the clinical development of IVDs. Christian also co-chairs the Working Group Clinical Evidence at MedTech Europe. He undertook his training in pharmacology at the University of Basel, Switzerland, and at the University of California San Francisco, USA. Christian has a PhD in Biomedical Research and Pharmacology from the University of Basel, where he also teaches as Professor of Experimental Cardiology at the Faculties of Medicine and Science. Prior to Roche, he worked at Speedel and ICON in Drug and Device Development.

Contact/Address

LinkedIn Url:

Contact: christian.zaugg@roche.com

Julia Schwarz

Title/Position:

Business Development manager



Background/CV

Julia Schwarz is a Business Development Manager at Roche Diagnostics Partnering responsible for assessing and accessing external innovation.

Julia is a trained biologist from Philipps-University-Marburg, Germany. She has a PhD in Biology from the Max-Planck-Institute of terrestrial Microbiology and the Philipps-University of Marburg.

Julia joined Roche Diagnostics in 2007 and worked in various roles in Research & Development before taking on her current position in Roche Diagnostics Partnering in 2012. As part of this role, she is interested in exploring and entering into partnerships with ^{3rd} parties such as research collaborations, supply agreements or license agreements.

Contact/Address

LinkedIn Url:

Contact: julia.schwarz@roche.com

Markus Riessler

Title/Position:

Head R&D early development



Background/CV

Markus Roeßler, PhD

Graduated in Microbiology at the Georg-August University, Göttingen, Germany

PhD from the Ludwig-Maximilians-University, Munich, Germany

Joined Roche in 2002 and worked in various Early Development projects for almost 20 years. Experienced in Marker Discovery, Immunoassay Development, System Development and Innovation Management. Currently, responsible for leading an RnD department with ~90 FTE over two sites, which deals with the complete range of Early Development pipeline from Markers to Systems.

Contact/Address

LinkedIn Url:

Contact: markus.roessler@roche.com

Olivier PERCHE

Title/Position:

Public Affairs and Market Access Manager



Background/CV

In diagnostic field of play since more than 30 years through sales, marketing, supply chain, quality and regulatory positions efore focusing myself on market access and public affairs activities.

Contact/Address

LinkedIn Url:

Contact: olivier.perche.op1@roche.com



Number of Countries Present in 100 countries
Headquarters 54-56 Rue la Boétie 75008 Paris France
Company Size More than 100,000 employees
R&D Staff 4 086
Annual Sales 2020 €36,126M in 2019
R&D Investment €6,022M in 2019

>> Company description

We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. Sanofi, Empowering Life.

>> Therapeutic areas of interest including R&D listed by priority

Three core business units support the company's strategy. CHC will be a standalone business unit with integrated R&D and manufacturing functions:

- Specialty Care: Immunology-Rare Diseases / Rare Blood Disorders-Neurology / Multiple Sclerosis - Oncology
- General Medicines: Diabetes-Cardiovascular-Established Products
- Vaccines: Influenza vaccines - Polio Pertussis & Hib, Boosters - Meningitis, others
- Consumer Healthcare: Allergy, Cough & Cold-Pain-Digestive-Nutritionals

>> History of collaboration with academic teams or startups

Sanofi is active in the quest for new ideas and solutions in immunology. We are seeking therapeutics to normalize immune responses in immune-mediated disorders such as rheumatic (such as rheumatoid arthritis, systemic lupus erythematosus...), respiratory (like severe asthma, COPD...), inflammatory skin (including atopic dermatitis) and gastrointestinal diseases (i.e. Inflammatory Bowel Disease). We are proud of our collaboration with Regeneron, through which we launched Dupixent® (dupilumab), a first-in-class biologic drug to treat atopic dermatitis and severe asthma.

We are looking for partners who share our focus on biologics, small molecules and nucleic acid-based approaches and with whom we can make a difference.

<https://www.sanofi.com/en/science-and-innovation/partnering>

>> Keywords

Dermatological and Pulmonary Disorders | Rheumatological Disorders | Gastrointestinal Disorders | |

BIESEMANN Nadine

Title/Position:

Thematic Leader Immunometabolism



Background/CV

Nadine joined Sanofi in 2014 and is currently Distinguished Scientist and Thematic Leader Immunometabolism in the Immunology and Inflammation Research Department. She holds a Ph.D. from Max-Planck-Institute/University Mainz and is highly interested in novel metabolic targets for the treatment of autoimmune diseases. In addition she's involved in several academic collaborations and IMI consortia to decipher pathways and immune cell subsets driving disease progression and non-response in rheumatic diseases. Her aim is to translate this knowledge into better and innovative therapies for patients.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/nadine-biesemann-88a67397/>

Contact: Nadine.Biesemann@sanofi.com

CRESPO Laia

Title/Position:

Head of Investments Europe - Sanofi Ventures



Background/CV

Laia joined Sanofi Ventures in 2018 with a background in biotech investing primarily in Europe. Prior to Sanofi, Laia served as Investment Director for Ysios Capital, a Venture fund based in Barcelona, where she led investments and served on the Boards of OxThera (Sweden), Minoryx Therapeutics (Spain) and Inbiomotion (Spain), and as an Observer with AM-Pharma (The Netherlands). Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia currently serves as a board observer for NodThera and Lava Therapeutics.

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/laiacrespo/>

Contact: laia.crespo@sanofi.com

De LAJUDIE Victoire

Title/Position:

Franchise Head Dupixent France - Sanofi Genzyme



Background/CV

Victoire De Lajudie is the Franchise Head Dupixent France

Victoire joined Sanofi in 2009 in the Strategy and Business Development department where she held several roles, both in the Region and in subsidiaries, in Europe, France and China. Victory arrived in Belgium in 2018 as Head of the Business Unit Cardiovascular disease BeLux; then, in 2019, she was appointed BeNeLux Primary Care Marketing Manager.

Prior to joining Sanofi, Victoire worked as a consultant at McKinsey and Co. She holds a master's degree from The Polytechnic (France) and a master's degree in management from the University of Cambridge (UK).

Experience in strategy/finance/digital & marketing/sales; at international & national levels (incl. China and Belgium/Netherlands). Passionate about modernizing healthcare from both product and service standpoints.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/victoire-de-lajudie-8768101/>

Contact: Victoire.delajudie@sanofi.com

De RINALDIS Emanuele

Title/Position:

Head of Precision Immunology



Background/CV

Emanuele de Rinaldis, Ph.D.

Dr Emanuele de Rinaldis is a Senior Director and Head of Precision Immunology at Sanofi since November 2017.

Emanuele was educated at the University of Rome “La Sapienza” where he received an MSc in Molecular Biology and a PhD in Biochemistry & Bioinformatics.

With his team at Sanofi, Emanuele is advancing research programs for the identification of novel therapeutic targets and biomarkers in immune conditions, using systems immunology and single-cell approaches and leveraging immune profiling, genomics and clinical data to develop novel targeted and personalized immune therapies.

Throughout his career he has published over 50 articles in journals such as Bioinformatics, Nature Communications, Human Molecular Genetics, Blood, Lancet and Immunity.

Prior to joining Sanofi, he was the BRC Head of Translational Bioinformatics & Honorary Senior Lecturer (Associate Professor) at the King’s College of London. From 2003-2009, he was a Senior Scientist at Merck Sharp & Dohme (US), directing a team for the identification of novel therapeutic targets/pathways in oncology. During 1999-2002 he was at LION Bioscience in Heidelberg (GE) where - as Scientific Software Engineer - he developed bioinformatics methods for the analysis of protein structures, microarray data, pathways and DNA polymorphisms.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/emanuele-de-rinaldis-503b31/>

Contact: Emanuele.deRinaldis@sanofi.com

GUIS Monique

Title/Position:

Director External Innovation Immunology, Sanofi Partnering



Background/CV

Monique GUIS is an External Innovation Director for Immunology at Sanofi since 2015. She is searching and evaluating global external partnering opportunities in the research, development and commercial space in immunology in order to strengthen Sanofi Immunology portfolio. She set-up several partnerships such as public private partnerships or pre-competitive consortia and asset in-licensing.

Previously she managed R&D teams in several areas covering agronomy (plant breeding and plant biotechnology) and pharma (obesity, diabetes, regenerative medicine...) mainly at Sanofi and at Rhobio, a joint-venture between Aventis Crop Science and Biogemma.

Monique holds an engineering degree and a PhD in Plant Science. She did postdoctoral fellowships at Davis University, California and at CPRO-DLO in Wageningen, The Netherlands. She holds an executive MBA from Internal Institute of Management, Paris.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/monique-guis-b9a40a5/>

Contact: monique.guis@sanofi.com

MARRACHE Frederic

Title/Position:

Global project head - Clinical development - Immunology and inflammation
Therapeutic area



Background/CV

Frederic Marrache is MD. PhD and also holds an MBA from INSEAD. He trained as a gastroenterologist at AP-HP and obtained his PhD from Université Paris VII. He subsequently did a post doc at Columbia University where he studied the link between chronic inflammation and carcinogenesis. At Sanofi, he leads several early to mid-stage programs targeting immune driven diseases.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/frederic-marrache-46a848b/>

Contact: Frederic.marrache@sanofi.com

PASQUIER Benoit

Title/Position:

Head of Checkpoint Immunology France group



Background/CV

Benoit Pasquier Ph.D.

Benoit Pasquier is currently the Head of Checkpoint Immunology France at Sanofi. He is leading a group of 10 scientists focused on discovering and developing therapeutics for immunology and inflammation research therapeutic area. He is also leading projects in collaboration with academic laboratories: CIML (Marseille), Imagine Institute (Necker Hospital). Benoit is working at Sanofi since 15 years in Drug Discovery with experiences in projects in Oncology, Immuno-Oncology and Immuno-inflammation therapeutic areas. Prior to joining Sanofi he was working in IDM Pharma, a biotech that was dedicated to Dendritic cells and Cancer Immunotherapy. Benoit has a background in Immunology with a PhD from University of Paris and had a Postdoctoral fellow with Professor Alain Fischer at Necker Hospital in Paris. Since 2013, Benoit Pasquier is an adjunct associate Professor in Immunology at Sorbonne University in Paris.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/benoit-pasquier-03371529/>

Contact: benoit.pasquier@sanofi.com

RAMADAS Ravi



Title/Position:

Head of Immunology External Innovation, Sanofi Partnering, Sanofi

Background/CV

Ravi is the Head of Immunology External Innovation at Sanofi. In this capacity he oversees global external partnering opportunities in the research, development and commercial space in immunology, working closely with colleagues from R&D, Commercial, Strategy, Business Development, Ventures and Mergers & Acquisitions to build and advance the Sanofi Immunology portfolio. Prior to this role, Ravi contributed to and managed R&D teams, programs and portfolios in the immunology and immuno-oncology therapeutic areas at Sanofi, Jounce Therapeutics and Merck Research Laboratories, following postdoctoral fellowships in University of Florida and Harvard Medical School. Ravi holds a PhD from Michigan State University, a DVM from Madras Veterinary College and is currently enrolled in the executive MBA program at the MIT Sloan School of Management. Ravi enjoys mentoring young professionals, identifying and fostering cutting-edge science and has a broad interest in the life sciences sector.

Contact/Address

LinkedIn Url:

Contact: ravi.ramadas@sanofi.com

SAVOVA Virginia

Title/Position:

Head of Single-Cell Biology Lab, Precision Immunology



Background/CV

Dr. Virginia Savova joined Sanofi from the Harvard Medical School in 2017, establishing a lab combining single-cell omics and artificial intelligence to uncover disease-related changes in immune cells. She is currently the co-chair of AMP-AID- an NIH initiative which brings together clinicians, academics and industry experts seeking to apply these technologies to a broad range of autoimmune and inflammatory diseases

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/vsavova/>

Contact: Virginia.Savova@sanofi.com

SCHNEIDER Véronique

Title/Position:

Medical Director France -Sanofi Genzyme



Background/CV

Dr Veronique Schneider is France Medical Director leading the medical affairs team for Sanofi Genzyme France. She is driving all the medical affairs activities, including new product launch initiatives, execution of medical plans and maintaining medical governance. Veronique brings more than 20 years of experience in pharmaceutical industry, having held positions of increasing responsibility in medical and marketing departments. She has a strong expertise in launching new products and implementing competitive strategies across multiple therapeutic areas. In his last role, she drove the Rare Disease and Rare Blood Disorder Medical Team, actively preparing the coming launches for eliglustat, olipudase alpha, avalglucosidase and sutimlimab.

Prior to joining Sanofi, Veronique was working as medical manager for Novartis company. In this role, she led the launch of two new indications for Lucentis block buster. Before joining Novartis, Veronique held various roles at Alcon, Servier and BBraun.

Véronique holds a Medical Doctorate from Paris VII University with an Advanced Master degree in Marketing Management from ESP Business School.

Experience in medical/ marketing and sales / market access / Development

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/schneider-veronique-md-5a768553/>

Contact: veronique.schneider@sanofi.com

STOREK Michael J.

Title/Position:

Complement Cluster Head, Immunology and Inflammation Research, Sanofi



Background/CV

Michael received a B.S. in chemistry followed by an M.S. in biochemistry at Charles University, Prague (Czech Republic). After graduation, he moved to the US and worked as a research associate at Emory University. Next, he studied protein-DNA complexes as a graduate student in the laboratory of Gregory Verdine at Harvard University. Michael has 18 years of industry experience, of which 11 years are Complement system related. He worked at Taligen Therapeutics as the Lab Head and after Taligen's acquisition by Alexion, he continued working on novel Complement inhibitors and leading due diligences of many other Complement companies. After Alexion, he consulted for several leading venture capital companies and worked at the start-up, Admirx. Michael joined Sanofi in November 2019 as the Head of the Complement Research Cluster. He loves French art and history of 18th and early 19th century, unfortunately he does not speak nor read French.

Contact/Address

LinkedIn Url: www.linkedin.com/in/michaelstorek/

Contact: Michael.Storek@Sanofi.com

VOLCKMANN Jacques

Title/Position:

Head R&D France



Background/CV

Jacques Volckmann, is a Doctor in Pharmacy, holds a master in microbiology from the Lyon Industrial Pharmaceutical Institute (IPIL) and a master in fundamental virology from the Lyon I University. He is also graduated from the CEDEP/INSEAD in Business Administration.

He has a developed experience in several domains such as Production, Analytic Sciences, Quality, Product Development, mostly in Biologic Products (hormones, vaccines...).

From 2007 to 2009, he was appointed as the R&D Director of the Sanofi Pasteur sites based in France. From 2010 to 2014, he was appointed as the Europe New Vaccines Project Director at Sanofi Pasteur, in charge of overseeing development of projects for new vaccines belonging to the Global Development Portfolio. From 2014 to end 2017, he held various positions as Director of the Global R&D Sites, Hubs and Scientific Support Units at Sanofi Pasteur. Since April 2018, Jacques is appointed as Head of R&D France with a direct oversight on the Sanofi R&D Sites in France.

He is a member of the Sanofi R&D Management Committee (MCom) and of the Sanofi French Strategic Committee. He is also the president of the 'Biopark by Sanofi' in Toulouse. He is the President of the Board of the Pharmaceutical and Biologics Institute of Sciences in Lyon (ISPB/ Faculté de Pharmacie de Lyon), member of the board of the Bioaster Institute in Lyon (IRT), and a member of the board of the Ksilink Research Institute in Strasbourg.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/jacques-volckmann-3361b21a/>

Contact: Jacques.Volckmann@sanofi.com



Number of Countries 150
Headquarters Suresnes, France
Company Size 22,000
R&D Staff
Annual Sales 2020 €4.6Bn
R&D Investment 700M€

>> **Company description**

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: immune-inflammatory, neurodegenerative diseases, and cancer, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

>> **Therapeutic areas of interest including R&D listed by priority**

Cancer
Immuno-inflammation
Neurodegenerative diseases

>> **History of collaboration with academic teams or startups**

An on-going history, with currently 30+ partnerships and 40+ research collaborations worldwide, both with academic teams, start-ups and biotech companies.

>> **Keywords**

Patient health | Cancer | Immuno-inflammation | Neurodegenerative diseases | Partnerships

Allinne Jeanne

Title/Position:

Head of Immuno-inflammation Research



Background/CV

Jeanne ALLINNE received her PhD in oncology from Paris XI University, studying the epigenetics of B cell Lymphoma. After her postdoctoral training at NYU (New York, USA), where she focused on mechanisms of chromosomal translocations during B and T cells development, she joined Regeneron Pharmaceuticals (Tarrytown, USA) where she held positions of increasing responsibility in the department of Immunology and Inflammation. In particular, she was responsible for the preclinical validation and early clinical development of several therapeutic monoclonal antibodies that are marketed (dupilumab) or still in development today, mainly in the field of respiratory and allergic diseases, but also in the field of solid organ transplant and auto-immune diseases. She joined Servier in 2019, Currently leading the Immuno-inflammation Research Team, to help build Servier's expertise and portfolio in the field of autoimmune and fibrotic diseases.

Contact/Address

LinkedIn Url:

Contact: jeanne.allinne@servier.com

Dupin-Roger Isabelle



Title/Position:

Opportunities and Potential Partnerships Director

Background/CV

Isabelle DUPIN-ROGER received her Pharmacist degree from Paris XI University and a Master of Sciences degree from Paris VI. She was formerly Resident of Paris Hospitals (1989-1993).

She has more than 20 years of experience in pharmaceutical industry, holding several positions in Servier Research and Development in Rheumatology and Immune-inflammatory field. She has notably contributed to the worldwide development, filing procedures and launching of one drug and one patent application. She has also contributed to numerous publications and poster communications.?

She is currently Director of Opportunities and Potential Partnerships for immuno-inflammatory disease at Servier, in charge of scouting and evaluation in the field of Rheumatology, Immuno-Inflammation & Auto-Immune Diseases for licensing-in opportunities.

Contact/Address

LinkedIn Url:

Contact: isabelle.dupin-roger@servier.com

Jeggo Ross



Title/Position:

Head of Neurology and Immunoinflammation Therapeutic Area, R&D

Background/CV

After completing a PhD in neuroscience at University College London, I started my career at a start-up Biotech company called Neurosolutions based at the University of Warwick in the UK, where my initial focus was to establish an electrophysiological platform to study synaptic impairments induced by beta-amyloid oligomers. Over the following 10 years at Neurosolutions, I worked across several therapeutic domains including pain, depression, epilepsy, schizophrenia, and both Alzheimer's and Parkinson's disease, delivering to internal drug discovery projects and working externally in a fee-for-service format with many partners across the biotech and pharmaceutical industry. With a significant passion to find effective treatments for neurological disease, I then moved closer to drug development by joining Lundbeck, a Danish pharmaceutical company focused on the neurosciences. As a Research Director based in Copenhagen, over a period of 4 years I led a research department working on a range of projects from exploratory research to late stage clinical development in neurodegenerative disease and including both small molecule and immunotherapy-based approaches. With the experience gained in industrial drug discovery and development, targeting pathological proteins that contribute to neurodegenerative disease, I moved to Servier in 2017. Here in France, I initially led a drug discovery team bringing forward new treatments for proteinopathies targeting neurological disease before taking leadership in 2020 of a newly formed therapeutic area covering both neurology and Immunoinflammation across the full drug discovery and development spectrum. We currently have an expanding and progressing portfolio of around 20 internal and partnered projects and are committed to bringing forward our promising and innovative portfolio of novel candidates towards high unmet medical needs in these two domains.

Contact/Address

LinkedIn Url:

Contact: ross.jeggo@servier.com

Laigle Laurence

Title/Position:

Director of Clinical and Translational Research - Immuno-Inflammatory Diseases



Background/CV

Laurence Laigle received her Medical Degree from Paris-Diderot University after having completed a postgraduate degree with focus on Internal Medicine and emergency care unit. She then obtained a qualification in Immunology at APHP Paris University.

She is currently Director of Clinical and Translational Research in the immune-inflammatory diseases field at Servier leading the biomarker research strategy based on a Precision Medicine approach. She promotes actively Public Private Partnerships and academic collaborations to foster innovation. She was involved in the former PRECISESADS IMI project and co-lead the blood biomarker work package in the on-going NECESSITY IMI2 project.

She has an extensive expertise in drug development across several therapeutic areas acquired during the past thirty years within different companies (Eli Lilly, Novartis and Servier). In addition, before joining Servier she was involved as a medical Expert in Drug evaluation and therapeutic guidelines development at the French Regulatory Agency.

Among all her achievements she has contributed to the worldwide filing procedures of two drugs and to three patent applications. She has also contributed to publications and poster communications.

Contact/Address

LinkedIn Url:

Contact: laurence.laigle@servier.com

Olivier Nosjean

Title/Position:

Head of Open Innovation and Scientific Affairs, R&D



Background/CV

Olivier Nosjean is the Head of Open Innovation and Scientific Affairs at Servier R&D. A biochemist by training, he has been a drug discovery researcher and manager for 20 years. He established and has been a contributor to a range of public/private partnerships throughout the world, focused on therapeutic innovation and on scientific and technology expertise. Olivier is currently leading the technology innovation strategy and the Program for PhD students and Post-docs at Servier. He is coordinating the initiatives at Servier related to open innovation, entrepreneurship and public-private partnerships. One of his most exciting actions today are dedicated to preparing the opening of a drug discovery incubator along the new research site of Servier currently under construction. Along with his actions at the interface with a range of public and private partners, Olivier Nosjean has recently taken the role of Scientific Affairs for R&D, liaising with the actors of the vibrant ecosystem of innovation in health sciences.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/olivier-nosjean-98963a3>

Contact: olivier.nosjean@servier.com

Philippe Moingeon

Title/Position:

Head of Immunoinflammation portfolio



Background/CV

Philippe MOINGEON received his PhD in immunology from Paris XI University, and an MBA from Open University Business School (UK). He was formerly Resident of Paris Hospitals (1981-1986), Post-doctoral fellow (1987-1990) and Assistant Professor at Harvard Medical School (Boston, USA, 1991-1994).

He has extensive experience in the development of biologicals, holding several positions in the vaccine industry, including Director for the cancer vaccine program and General Secretary for Research and Development, at Aventis Pasteur(1994-2003), as well as Senior Vice President, Research and Pharmaceutical Development at Stallergenes SA (2003-2017).

Two vaccines registered in Europe, USA and Japan, 210 scientific publications in peer-reviewed journals, 24 patents/ patent applications.

He joined Servier in September 2017, to head the Center for Therapeutic Innovation for immuno-inflammatory diseases.

Current scientific interests: drug development for auto-immune and inflammatory diseases, human immunology, applications of artificial intelligence and computational modelling to drug development.

Contact/Address

LinkedIn Url:

Contact: philippe.moingeon@servier.com



Number of Countries approximately 80
Headquarters Tokyo, Japan
Company Size approximately 50 000 employees
R&D Staff approximately 5 000 employees
Annual Sales 202030 bio US\$
R&D Investment 4.5 bio US\$

>> **Company description**

Patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan

>> **Therapeutic areas of interest including R&D listed by priority**

Gastroenterology
Oncology
Rare Genetic and Hematology
Neuroscience

>> **History of collaboration with academic teams or startups**

Over 200 active partnerships

>> **Keywords**

Enteric neuroinflammation | Liver fibrosis | IBD (Crohn's and Ulcerative Colitis) and Celiac Disease | Targeted cell delivery technologies | Immune modulation

Antara Banerjee

Title/Position:

Associate Director GI Immunology, Immunobiologics Lead, GI



Background/CV

Passionate Immunologist and a strategic leader with over 15 years of experience in large pharma leading portfolio strategy in Immunology and Biologics for GI Inflammation (IBD/Celiac) and Oncology. Proven expertise in leading programs and advancing various therapeutic modalities including antibodies, cell therapies, fusion proteins, peptides and small molecules from preclinical discovery into early development. My career at Takeda is underlined by succession to positions of increasing responsibility where I have served as Group Leader at the local and global levels of Global Biologics Discovery and Engineering and the Global Immunology Network. Proven achievements in hiring and building high functional teams across geographies (San Francisco, San Diego and Boston) and championing talent development to build organizational capability. I have also contributed to a number of Takeda's clinical stage programs as a discovery lead and in driving the asset and translational strategy. I currently serve on the Inflammation leadership team and my team is responsible for developing mechanism based cellular and molecular in vitro assays to support translational activities and screening of therapeutic candidates for GI Inflammation. I have significant experience leading cross functional project teams and due diligence activities across therapeutic areas and I have served as a key contributor on a number of successful Takeda partnerships including Maverick, Shattuck, Memorial Sloan Kettering, Mersana ADC, Teva Attenuekine, Adimab, Trianni etc.

My core leadership strengths are my integrity, my passion, and my can-do attitude. My character integrity is my North Star that defines everything I do as a leader and as a professional. I come to work every day with a deep passion about science and the human race's relentless pursuit of cures for the most difficult and debilitating diseases. This passion makes me resilient, temper successes with disappointments and keeps me going with the big picture view, day in and day out. As a strategic and scientific leader, I can look beyond an individual project to see how it is connected to an overall purpose and be creative or decisive when required. I am a trusted leader of people who promotes a team work environment to engage talented and multidisciplinary teams, internally and with business partners to bring innovative and novel medicines to patients.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/antarab/>

Contact: antara.banerjee@takeda.com

Ewan Taylor

Title/Position:

Associate Scientific Director, GI



Background/CV

Cross functional team leader with expertise in drug discovery, immunology, oncology, gastroenterology and translational sciences.

Contact/Address

LinkedIn Url:

Contact: ewan.taylor@takeda.com

Jean Delonca

Title/Position:

Medical Director, Takeda France



Background/CV

Jean is an MD with a specialization in cardiovascular disease and holds an Executive MBA from the ESSEC Business School in Paris. He has more than 25 years of experience in the pharmaceutical industry. After 7 years of medico-marketing and 3 years of R&D activities, he transitioned to the Medical Affairs space where he has held positions of increasing responsibilities, both at the local and the regional level. After joining Shire almost 6 years ago as Country Medical Director, he successfully contributed to the integration of Baxalta which was acquired by Shire followed by the integration of Shire within Takeda a couple of years ago.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/jean-delonca-37370b6/?originalSubdomain=fr>

Contact: jean.delonca@takeda.com

Kristen Lorentz

Title/Position:

Search & Evaluation Lead, GI, Center for External Innovation



Background/CV

Kristen has a PhD in Bioengineering and over 15 years of experience in life science R&D, including in the domains of immunology, regenerative medicine, and platform technology development. She has co-founded two biotech companies focused on immune tolerance, Anokion and Kanyos Bio, where she played a leading role in company creation and in the successful development and translation of innovative technologies from concept to clinic. During her time there, Kristen strategically built and led teams and R&D sites in the U.S. and Switzerland, drove collaborations with biopharma and academic partners, supported financing efforts, and led development efforts in diverse disease areas. Earlier in her career, Kristen contributed to building and launching inaugural bioengineering laboratory courses at a technology institute. She joined Takeda's Center for External Innovation R&D Business Development team as a Search & Evaluation Lead in May 2020.

Contact/Address

LinkedIn Url: <https://linkedin.com/in/KristenLorentz>

Contact: kristen.lorentz@takeda.com

Marie Malcles

Title/Position:

Medical Advisor, Genetic Diseases, Takeda France



Background/CV

Marie Malcles has 15 years of experience in Hematology, oncology and immune-oncology. She has a PhD in viral oncology and has worked in fundamental and translational research for several years in France and in Cancer institute, UCL in London. Then, she joined as a consultant in launch strategy in specialty care and onco-hematology in several consulting companies. She joined pharmaceutical companies in different roles, both at European level and local level, in transversal roles and medical affairs. She has developed strong skills in medical education, KOL management and launch strategy. She joined Takeda as a medical advisor in genetic disease in April 2020.

Contact/Address

LinkedIn Url: <https://www.linkedin.com/in/marie-malcles/?originalSubdomain=fr>

Contact: marie.malcles@takeda.com

MARCH 16-17 2021

IMMUNOLOGY & INFLAMMATORY DISORDERS

100% DIGITAL EXPERIENCE

Contact

contact@hybridays.com

WWW.HYBRIDAYS.COM